Marco Massari to Male
This is a "connection" page, showing publications Marco Massari has written about Male.
Connection Strength
0.071
-
Abdominal Visceral Infarction in 3 Patients with COVID-19. Emerg Infect Dis. 2020 Aug; 26(8):1926-1928.
Score: 0.012
-
Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. Rheumatology (Oxford). 2021 10 09; 60(SI):SI25-SI36.
Score: 0.003
-
The impact of chest CT body composition parameters on clinical outcomes in COVID-19 patients. PLoS One. 2021; 16(5):e0251768.
Score: 0.003
-
The value of computed tomography in assessing the risk of death in COVID-19 patients presenting to the emergency room. Eur Radiol. 2021 Dec; 31(12):9164-9175.
Score: 0.003
-
Are Individuals with Substance Use Disorders at Higher Risk of SARS-CoV-2 Infection? Population-Based Registry Study in Northern Italy. Eur Addict Res. 2021; 27(4):263-267.
Score: 0.003
-
High-dose glucocorticoids pulse-therapy for beta-coronaviridae pneumonia: a systematic literature review and case-series of Coronavirus disease-2019. Clin Exp Rheumatol. 2021 Sep-Oct; 39(5):1119-1125.
Score: 0.003
-
Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. PLoS One. 2021; 16(2):e0247275.
Score: 0.003
-
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021 01 01; 181(1):24-31.
Score: 0.003
-
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients. Drug Saf. 2020 12; 43(12):1297-1308.
Score: 0.003
-
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med. 2020 10 21; 18(1):405.
Score: 0.003
-
TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. Contemp Clin Trials. 2020 11; 98:106165.
Score: 0.003
-
Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care. 2020 09 29; 24(1):589.
Score: 0.003
-
Accuracy of CT in a cohort of symptomatic patients with suspected COVID-19 pneumonia during the outbreak peak in Italy. Eur Radiol. 2020 Dec; 30(12):6818-6827.
Score: 0.003
-
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis. 2020 07; 79(7):986-988.
Score: 0.003
-
Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 06 11; 382(24):2327-2336.
Score: 0.003
-
The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort. Dig Liver Dis. 2019 03; 51(3):438-442.
Score: 0.003
-
The potential impact of multidimesional geriatric assessment in the social security system. Aging Clin Exp Res. 2018 Oct; 30(10):1225-1232.
Score: 0.003
-
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS One. 2017; 12(10):e0185728.
Score: 0.002
-
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group. Infez Med. 2017 Jun 01; 25(2):150-157.
Score: 0.002
-
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One. 2017; 12(2):e0172159.
Score: 0.002
-
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat Med. 2017 Mar; 23(3):327-336.
Score: 0.002
-
Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol. 2002 Dec; 76(24):12423-34.
Score: 0.001